CRIS Quote, Financials, Valuation and Earnings

Armata Pharmaceuticals, Inc. has a net margin of -243.36% compared to Curis, Inc.'s net margin of -2301.55%. Curis, Inc.'s return on equity of -461.34% beat Armata Pharmaceuticals, Inc.'s return on equity of --.

Curis, Inc. has a consensus price target of $14.00, signalling upside risk potential of 1233.33%. On the other hand Armata Pharmaceuticals, Inc. has an analysts' consensus of $9.00 which suggests that it could grow by 40.41%. Given that Curis, Inc. has higher upside potential than Armata Pharmaceuticals, Inc., analysts believe Curis, Inc. is more attractive than Armata Pharmaceuticals, Inc..

Curis, Inc. has a beta of 4.025, which suggesting that the stock is 302.512% more volatile than S&P 500. In comparison Armata Pharmaceuticals, Inc. has a beta of 1.240, suggesting its more volatile than the S&P 500 by 23.97%.

Curis, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Armata Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Curis, Inc. pays -- of its earnings as a dividend. Armata Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Curis, Inc. quarterly revenues are $3.2M, which are larger than Armata Pharmaceuticals, Inc. quarterly revenues of $1.2M. Curis, Inc.'s net income of -$7.7M is higher than Armata Pharmaceuticals, Inc.'s net income of -$26.7M. Notably, Curis, Inc.'s price-to-earnings ratio is -- while Armata Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Curis, Inc. is 1.00x versus 53.17x for Armata Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Perspective Therapeutics, Inc. has a net margin of -243.36% compared to Curis, Inc.'s net margin of -12425.36%. Curis, Inc.'s return on equity of -461.34% beat Perspective Therapeutics, Inc.'s return on equity of -37.63%.

Curis, Inc. has a consensus price target of $14.00, signalling upside risk potential of 1233.33%. On the other hand Perspective Therapeutics, Inc. has an analysts' consensus of $12.3077 which suggests that it could grow by 338%. Given that Curis, Inc. has higher upside potential than Perspective Therapeutics, Inc., analysts believe Curis, Inc. is more attractive than Perspective Therapeutics, Inc..

Curis, Inc. has a beta of 4.025, which suggesting that the stock is 302.512% more volatile than S&P 500. In comparison Perspective Therapeutics, Inc. has a beta of 1.222, suggesting its more volatile than the S&P 500 by 22.249%.

Curis, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Curis, Inc. pays -- of its earnings as a dividend. Perspective Therapeutics, Inc. pays out -- of its earnings as a dividend.

Curis, Inc. quarterly revenues are $3.2M, which are larger than Perspective Therapeutics, Inc. quarterly revenues of $209K. Curis, Inc.'s net income of -$7.7M is higher than Perspective Therapeutics, Inc.'s net income of -$26M. Notably, Curis, Inc.'s price-to-earnings ratio is -- while Perspective Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Curis, Inc. is 1.00x versus 190.53x for Perspective Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Electromed, Inc. has a net margin of -243.36% compared to Curis, Inc.'s net margin of 12.65%. Curis, Inc.'s return on equity of -461.34% beat Electromed, Inc.'s return on equity of 18.89%.

Curis, Inc. has a consensus price target of $14.00, signalling upside risk potential of 1233.33%. On the other hand Electromed, Inc. has an analysts' consensus of $36.00 which suggests that it could grow by 25.31%. Given that Curis, Inc. has higher upside potential than Electromed, Inc., analysts believe Curis, Inc. is more attractive than Electromed, Inc..

Curis, Inc. has a beta of 4.025, which suggesting that the stock is 302.512% more volatile than S&P 500. In comparison Electromed, Inc. has a beta of 0.259, suggesting its less volatile than the S&P 500 by 74.113%.

Curis, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Curis, Inc. pays -- of its earnings as a dividend. Electromed, Inc. pays out -- of its earnings as a dividend.

Curis, Inc. quarterly revenues are $3.2M, which are smaller than Electromed, Inc. quarterly revenues of $16.9M. Curis, Inc.'s net income of -$7.7M is lower than Electromed, Inc.'s net income of $2.1M. Notably, Curis, Inc.'s price-to-earnings ratio is -- while Electromed, Inc.'s PE ratio is 30.91x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Curis, Inc. is 1.00x versus 3.83x for Electromed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Protalix Biotherapeutics, Inc. has a net margin of -243.36% compared to Curis, Inc.'s net margin of 13.19%. Curis, Inc.'s return on equity of -461.34% beat Protalix Biotherapeutics, Inc.'s return on equity of 12.06%.

Curis, Inc. has a consensus price target of $14.00, signalling upside risk potential of 1233.33%. On the other hand Protalix Biotherapeutics, Inc. has an analysts' consensus of $11.00 which suggests that it could grow by 521.47%. Given that Curis, Inc. has higher upside potential than Protalix Biotherapeutics, Inc., analysts believe Curis, Inc. is more attractive than Protalix Biotherapeutics, Inc..

Curis, Inc. has a beta of 4.025, which suggesting that the stock is 302.512% more volatile than S&P 500. In comparison Protalix Biotherapeutics, Inc. has a beta of -0.248, suggesting its less volatile than the S&P 500 by 124.798%.

Curis, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protalix Biotherapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Curis, Inc. pays -- of its earnings as a dividend. Protalix Biotherapeutics, Inc. pays out -- of its earnings as a dividend.

Curis, Inc. quarterly revenues are $3.2M, which are smaller than Protalix Biotherapeutics, Inc. quarterly revenues of $17.9M. Curis, Inc.'s net income of -$7.7M is lower than Protalix Biotherapeutics, Inc.'s net income of $2.4M. Notably, Curis, Inc.'s price-to-earnings ratio is -- while Protalix Biotherapeutics, Inc.'s PE ratio is 25.47x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Curis, Inc. is 1.00x versus 2.25x for Protalix Biotherapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.